<DOC>
	<DOCNO>NCT00953862</DOCNO>
	<brief_summary>Although Attention Deficit/ Hyperactive Disorder ( ADHD ) common comorbidity individual diagnose Substance Use Disorder ( SUD ) , little data currently exist utility screening tool large sample adult patient SUD inpatient treatment . This 10-week , 2-phase , open label trial atomoxetine ADHD adult patient treat co-morbid SUD residential treatment facility ( RTF ) . The primary objective study assess efficacy atomoxetine adult SUD ADHD . Secondary object include assessment co-morbidity ADHD safety tolerability atomoxetine population .</brief_summary>
	<brief_title>Atomoxetine/Attention Deficit/ Hyperactive Disorder ( ADHD ) /Substance Use Disorder ( SUD ) Residential Treatment Facility</brief_title>
	<detailed_description>Phase 1 : Patients SUD either newly admit ( abstinent &lt; 1 week ) treatment RTF ( abstinent &lt; 3 month ) administer Adult ADHD Self-Report Scale Symptom Checklist ( ASRS ) v. 1.1 Screener . Patients screen positive ( &gt; = 4 6 significant item ) administer Adult Clinician Diagnostic Scale ( ACDS ) v.1.2 establish diagnosis ADHD Predictive Value Positive ( PVP ) population . Phase II ( Treatment ) : Participants screen positive ADHD ACDS give informed consent baseline evaluation inclusion . Those meeting inclusion/exclusion criterion treat atomoxetine start 25 mg/day . The dose adjust base clinical response tolerability 4-week period 120 mg/day hold constant final six week trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Are age 1860 , inclusive . 2 . Meet diagnostic criterion substance dependence . 3 . Meet Diagnostic Statistics Manual Mental DisordersIV ( DSMIV ) criterion attention deficit hyperactivity disorder assess Adult ADHD Clinician Diagnostic Scale ( ACDS ) . 4 . Must able communicate effectively investigator study staff . 5 . Must able swallow capsule . 6 . Reside Odyssey House duration study . 1 . Lifetime present history bipolar disorder , schizophrenia schizoaffective disorder . Assessment make comprehensive psychiatric diagnostic interview . 2 . Have organic brain disease ( dementia ) traumatic brain injury residuum . Have history seizure disorder ( febrile seizure ) patient take ( currently take ) anticonvulsant seizure control . 3 . Females currently pregnant breast feeding , woman childbearing potential currently use adequate form birth control . 4 . Medical condition limit participation study . 5 . Patients serious suicidal homicidal risk . 6 . Have significant prior current medical condition could exacerbate compromised atomoxetine . 7. Who glaucoma . 8 . Have history difficulty start stream urine symptom suggestive prostate enlargement . 9. Who anticipate move travel extensively study period . 10 . Have medical condition would , opinion study physician , make participation medically hazardous . 11 . Be anyone opinion investigator would expect complete study protocol due probable incarceration relocation clinic area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Substance Use Disorder</keyword>
	<keyword>Residential Treatment Facility</keyword>
</DOC>